Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine, and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group-MedSci.cn

Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine, and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group

Nemcova, L; Nekvindova, L; Spacek, M; Simkovic, M; Papajik, T; Brejcha, M; Lysak, D; Zuchnicka, J; Novak, J; Starostka, D; Poul, H; Vrbacky, F; Urbanova, R; Panovska, A; Plevova, K; Pospisilova, S; Hrobkova, S; Koritakova, E; Smolej, L; Doubek, M

LEUKEMIA & LYMPHOMA, 2020; 61 (): 57

科室
- - 订阅+
  - 更多科室
工具
服务